These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 24277456)
21. Influence of vitamin D on cisplatin sensitivity in testicular germ cell cancer-derived cell lines and in a NTera2 xenograft model. Jørgensen A; Blomberg Jensen M; Nielsen JE; Juul A; Rajpert-De Meyts E J Steroid Biochem Mol Biol; 2013 Jul; 136():238-46. PubMed ID: 23098692 [TBL] [Abstract][Full Text] [Related]
22. Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine. Albany C; Hever-Jardine MP; von Herrmann KM; Yim CY; Tam J; Warzecha JM; Shin L; Bock SE; Curran BS; Chaudhry AS; Kim F; Sandusky GE; Taverna P; Freemantle SJ; Christensen BC; Einhorn LH; Spinella MJ Oncotarget; 2017 Jan; 8(2):2949-2959. PubMed ID: 27936464 [TBL] [Abstract][Full Text] [Related]
23. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines. Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062 [TBL] [Abstract][Full Text] [Related]
24. Tel/PDGFRbeta induces stem cell differentiation via the Ras/ERK and STAT5 signaling pathways. Dobbin E; Graham C; Corrigan PM; Thomas KG; Freeburn RW; Wheadon H Exp Hematol; 2009 Jan; 37(1):111-121. PubMed ID: 19100521 [TBL] [Abstract][Full Text] [Related]
25. Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours. Cierna Z; Miskovska V; Roska J; Jurkovicova D; Pulzova LB; Sestakova Z; Hurbanova L; Machalekova K; Chovanec M; Rejlekova K; Svetlovska D; Kalavska K; Kajo K; Babal P; Mardiak J; Ward TA; Mego M; Chovanec M BMC Cancer; 2020 Jan; 20(1):17. PubMed ID: 31906898 [TBL] [Abstract][Full Text] [Related]
26. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells. Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343 [TBL] [Abstract][Full Text] [Related]
27. Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability. Ali AY; Kim JY; Pelletier JF; Vanderhyden BC; Bachvarov DR; Tsang BK Mol Carcinog; 2015 Nov; 54(11):1301-14. PubMed ID: 25154814 [TBL] [Abstract][Full Text] [Related]
28. Cordycepin-induced unfolded protein response-dependent cell death, and AKT/MAPK-mediated drug resistance in mouse testicular tumor cells. Chang MM; Pan BS; Wang CY; Huang BM Cancer Med; 2019 Jul; 8(8):3949-3964. PubMed ID: 31145545 [TBL] [Abstract][Full Text] [Related]
29. PEA‑15 contributes to the clinicopathology and AKT‑regulated cisplatin resistance in gastric cancer. Jiang X; Zhang C; Li W; Jiang D; Wei Z; Lv M; Xie X; Sun X Oncol Rep; 2019 Mar; 41(3):1949-1959. PubMed ID: 30569123 [TBL] [Abstract][Full Text] [Related]
30. Chemotherapeutic sensitivity of testicular germ cell tumors under hypoxic conditions is negatively regulated by SENP1-controlled sumoylation of OCT4. Wu YC; Ling TY; Lu SH; Kuo HC; Ho HN; Yeh SD; Shen CN; Huang YH Cancer Res; 2012 Oct; 72(19):4963-73. PubMed ID: 23002208 [TBL] [Abstract][Full Text] [Related]
31. Direct TGF-β1 signaling between activated platelets and pancreatic cancer cells primes cisplatin insensitivity. Chen H; Lan X; Liu M; Zhou B; Wang B; Chen P Cell Biol Int; 2013 May; 37(5):478-84. PubMed ID: 23584798 [TBL] [Abstract][Full Text] [Related]
32. p53 restoration can overcome cisplatin resistance through inhibition of Akt as well as induction of Bax. Kim CW; Lu JN; Go SI; Jung JH; Yi SM; Jeong JH; Hah YS; Han MS; Park JW; Lee WS; Min YJ Int J Oncol; 2013 Nov; 43(5):1495-502. PubMed ID: 23970333 [TBL] [Abstract][Full Text] [Related]
33. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways. Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949 [TBL] [Abstract][Full Text] [Related]
34. Platelet-derived growth factor activates porcine thecal cell phosphatidylinositol-3-kinase-Akt/PKB and ras-extracellular signal-regulated kinase-1/2 kinase signaling pathways via the platelet-derived growth factor-beta receptor. Taylor CC Endocrinology; 2000 Apr; 141(4):1545-53. PubMed ID: 10746662 [TBL] [Abstract][Full Text] [Related]
35. Pannexin1 inhibits autophagy of cisplatin-resistant testicular cancer cells by mediating ATP release. Yuan M; Yao Y; Wu D; Zhu C; Dong S; Tong X Cell Cycle; 2022 Aug; 21(15):1651-1661. PubMed ID: 35373707 [TBL] [Abstract][Full Text] [Related]
36. MK2206 potentiates cisplatin-induced cytotoxicity and apoptosis through an interaction of inactivated Akt signaling pathway. Sun D; Sawada A; Nakashima M; Kobayashi T; Ogawa O; Matsui Y Urol Oncol; 2015 Mar; 33(3):111.e17-26. PubMed ID: 25499922 [TBL] [Abstract][Full Text] [Related]
37. Characterization of the protein kinase C signal transduction pathway in cisplatin-sensitive and -resistant human small cell lung carcinoma cells. Basu A; Weixel K; Saijo N Cell Growth Differ; 1996 Nov; 7(11):1507-12. PubMed ID: 8930400 [TBL] [Abstract][Full Text] [Related]
38. Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer. Mueller T; Voigt W; Simon H; Fruehauf A; Bulankin A; Grothey A; Schmoll HJ Cancer Res; 2003 Jan; 63(2):513-21. PubMed ID: 12543810 [TBL] [Abstract][Full Text] [Related]
39. The forkhead transcription factor FOXO1 mediates cisplatin resistance in gastric cancer cells by activating phosphoinositide 3-kinase/Akt pathway. Park J; Ko YS; Yoon J; Kim MA; Park JW; Kim WH; Choi Y; Kim JH; Cheon Y; Lee BL Gastric Cancer; 2014; 17(3):423-30. PubMed ID: 24202965 [TBL] [Abstract][Full Text] [Related]
40. Concurrent blockade of NF-κB and Akt pathways potentiates cisplatin's antitumor activity in vivo. Sun H; Zheng X; Wang Q; Yan J; Li D; Zhou Y; Lin Y; Zhang L; Wang X Anticancer Drugs; 2012 Nov; 23(10):1039-46. PubMed ID: 22760211 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]